Nalador-500 (Sulprostone)

Sulprostone acts as an agonist at prostaglandin E2 (EP) receptors on uterine smooth‑muscle cells. Activation of these receptors raises intracellular calcium, leading to stronger, coordinated uterine contractions and cervical ripening, which are essential for labor induction and controlling postpartum bleeding.

The dosing regimen for Nalador-500 is determined by the prescribing clinician based on the specific indication, patient condition, and clinical guidelines. Healthcare professionals calculate the appropriate intravenous dose and infusion rate for each individual case.

Nalador-500 is intended for use in pregnant patients when uterine stimulation is required, such as for labor induction or medical abortion. Its safety in breastfeeding has not been established, so clinicians weigh the benefits against potential risks before prescribing.

To request Nalador-500, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nalador-500 (sulprostone) is a prostaglandin E2 analog, whereas oxytocin is a peptide hormone. Sulprostone often provides a more rapid and sustained uterine contraction, which can be advantageous in cases of uterine atony or when oxytocin alone is insufficient. Choice depends on clinical scenario and physician preference.

Nalador-500 should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and potency.

Nalador-500 is given by intravenous injection or infusion under direct medical supervision. The exact administration technique, rate, and monitoring parameters are defined by the treating clinician according to the indication and patient response.

Serious risks include uterine rupture, severe hypotension, and anaphylactic reactions. These events require immediate medical attention and close monitoring during and after administration, especially in patients with pre‑existing cardiovascular or respiratory conditions.

Nalador-500 is contraindicated in patients with known hypersensitivity to sulprostone or other prostaglandin analogs, and it should be used with extreme caution in individuals with severe cardiovascular disease, uncontrolled asthma, or active uterine infection.